Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders

money, dollar

The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.

Takeda agrees $2.3bn sale of Japanese consumer health unit

Takeda has joined the ranks of big pharma companies jettisoning consumer health businesses in order to concentrate on higher-margin prescription drugs.

The drugmaker is divesting Takeda Consumer Healthcare, which operates mainly in Japan, to private equity group Blackstone for 242 billion yen ($2.3 billion), with the deal expected to close in March of next year.

Takeda Consumer Healthcare sells OTC medicines and other health products with sales of 60 billion yen ($567 million) in fiscal 2019. Its top-selling products are Alinamin – a vitamin B1 preparation used to relieve eye fatigue and muscle pain that has been a staple for Japanese households for more than 60 years – and cold remedy Benza Block.

Takeda’s chief executive Christophe Weber

The deal adds to a drive at Takeda to pay down the sizeable debt it absorbed after taking over Shire in a $59 billion deal that closed in early 2019. It also comes after chief executive Christophe Weber said the sale of the consumer health unit was “unlikely” last year.

Since the mega-merger, Takeda has been steadily selling off over-the-counter (OTC) and mature prescription medicines on a piecemeal basis. Earlier this year it divested products with annual sales in Europe of around $230 million, plus two manufacturing plants in Denmark and Poland, to Danish drugmaker Orifarm in a $670 million deal.

That came after a $660 million divestment of OTC and prescription drugs – sold mainly in Russia and Commonwealth of Independent States (CIS) countries – to Germany’s Stada last year, and a similar $200 million sell-off to Acino in Near East, Middle East and Africa (NEMEA) countries.

The latest deal takes Takeda a big step closer to its strategic goal of divesting $10 billion in non-core assets, and Weber said it will allow the company to zero in on developing and selling medicines for its five key therapeutic areas – gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.

Weber added that Takeda Consumer Healthcare would benefit from the move as it deals with “an increasingly competitive consumer health care market in Japan.”

It’s the second transaction for New York-based Blackstone in Japan’s healthcare sector, coming after the private equity giant acquired specialty medicine and biosimilar company Ayumi Pharma last year for around $1 billion.

Atsuhiko Sakamoto, head of private equity for Blackstone Japan, said Takeda Consumer Healthcare is “well-positioned to grow its established brands in Japan and launch new and expanded product offerings,” adding: “we see tremendous potential for [the company] in Japan and throughout Asia.”

Other companies that have been exiting the consumer health business in recent years include Novartis, Merck KGaA, and Bristol-Myers Squibb as well as Pfizer and GlaxoSmithKline which have agreed to combine their respective business units into a joint venture intended for a future spin-off.

The post Takeda agrees $2.3bn sale of Japanese consumer health unit appeared first on .

Takeda to Divest its Consumer Health Unit to Blackstone for $2.3B in Japan

Shots:

  • Takeda and Blackstone sign an agreement to divest it consumer health care business unit for $2.3B. The transaction expected to be closed by Mar 31, 2021
  • The portfolio to be divested includes OTC medicines and health products along with its lead product in the region, Alinamin. Blackstone plans to develop the business together with current TCHC management and continue to employ its employees
  • The divestiture allows Takeda to refocus on its five key business areas and reduce debt after its $59 billion acquisition of Shire

Click here ­to­ read full press release/ article | Ref: Takeda | Image: StraitTimes

Blackstone’s $4.7B acquisition of Ancestry raises privacy questions

Ancestry, which grew from a genealogy tracking tool to offering DNA tests for a number of healthconditions, reached a deal to be acquired by Blackstone for $4.7 billion. But privacy advocates have raised concerns over the deal — namely, what would happen to users’ health data?